DrugPatentWatch Database Preview
TRINTELLIX Drug Profile
Which patents cover Trintellix, and what generic alternatives are available?
Trintellix is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and ninety-nine patent family members in forty-one countries.
The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. There are sixteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the vortioxetine hydrobromide profile page.
Summary for TRINTELLIX
| International Patents: | 199 |
| US Patents: | 10 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 104 |
| Clinical Trials: | 7 |
| Patent Applications: | 58 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for TRINTELLIX |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for TRINTELLIX |
| DailyMed Link: | TRINTELLIX at DailyMed |
Generic Entry Opportunity Date for TRINTELLIX
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Synonyms for TRINTELLIX
| 1-(2-((2,4-Dimethylphenyl)sulfanyl)phenyl)piperazine monohydrobromide |
| 1-(2-((2,4-Dimethylphenyl)thio)phenyl)piperazine hydrobromide |
| 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine-hbr |
| 1-[2-[(2,4-dimethylphenyl)thio]phenyl]piperazine hydrobromide |
| 1-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazine hydrobromide |
| 2796AH |
| 4-[2-(2,4-Dimethyl-phenylsulfanyl)-phenyl]-piperazine hydrobromide |
| 4-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazin-1-ium bromide |
| 960203-27-4 |
| AB0165485 |
| AC-28325 |
| AKOS016340374 |
| Brintellix |
| Brintellix (TN) |
| C18H22N2S.BrH |
| CHEBI:76015 |
| CHEMBL2107387 |
| CS-1472 |
| D10185 |
| EBD3080710 |
| FT-0696676 |
| HG-0011 |
| HY-15414A |
| KB-81459 |
| Lu AA 21004 hydrobromide;Lu AA21004 hydrobromide |
| Lu AA 21004|||1-[2-[(2,4-dimethylphenyl)thio]phenyl]-piperazine hydrobromide |
| Lu AA21004 (HBr) |
| Lu-AA-21004 |
| Lu-AA21004-(HBr) |
| MFCD22383961 |
| MolPort-023-298-793 |
| Piperazine, 1-(2-((2,4-dimethylphenyl)thio)phenyl)-, hydrobromide (1:1) |
| s8021 |
| SC-95551 |
| SCHEMBL237653 |
| TKS641KOAY |
| UNII-TKS641KOAY |
| VNGRUFUIHGGOOM-UHFFFAOYSA-N |
| Vortioxetine (hydrobromide) |
| Vortioxetine (Lu AA21004) HBr |
| Vortioxetine (Lu AA21004) hydrobromide |
| Vortioxetine HBr |
| Vortioxetine hydrobromide |
| Vortioxetine hydrobromide (JAN/USAN) |
| Vortioxetine hydrobromide [USAN] |
| vortioxetine monohydrobromide |
| W-5911 |
US Patents and Regulatory Information for TRINTELLIX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-004 | Sep 30, 2013 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-003 | Sep 30, 2013 | DISCN | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-004 | Sep 30, 2013 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-004 | Sep 30, 2013 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-004 | Sep 30, 2013 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-003 | Sep 30, 2013 | DISCN | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for TRINTELLIX
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 5 mg, 10 mg, 15 mgand 20 mg | ➤ Subscribe | ➤ Sign Up |
International Patents for TRINTELLIX
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Poland | 368442 | ➤ Sign Up |
| Spain | 2298425 | ➤ Sign Up |
| Mexico | 2009009672 | ➤ Sign Up |
| Portugal | 1436271 | ➤ Sign Up |
| Germany | 60233608 | ➤ Sign Up |
| European Patent Office | 2219647 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for TRINTELLIX
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 90023-7 | Sweden | ➤ Sign Up | PRODUCT NAME: VORTIOXETINE ELLER ETT FARMACEUTISKT GODTAGBART SYRAADDITIONSSALT DAERAV; REG. NO/DATE: EU/1/13/891 20131218 |
| 14/022 | Ireland | ➤ Sign Up | PRODUCT NAME: VORTIOXETINE OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF; REGISTRATION NO/DATE: EU/1/13/891 20131220 |
| 8 | Finland | ➤ Sign Up | |
| 2014013 | Lithuania | ➤ Sign Up | PRODUCT NAME: VORTIOXETINUM; REGISTRATION NO/DATE: EU/1/13/891 20131218 |
| 2014013,C1436271 | Lithuania | ➤ Sign Up | PRODUCT NAME: VORTIOKSETINAS ARBA JO FARMACINIU POZIURIU PRIIMTINA RUGSTIES PRISIJUNGIMO DRUSKA; REGISTRATION NO/DATE: EU/1/13/891 20131218 |
| 0652 | Netherlands | ➤ Sign Up | PRODUCT NAME: VORTIOXETINE OF EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT ERVAN; REGISTRATION NO/DATE: EU/1/13/891/001-036 20131218 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
